Jiangsu Nhwa Pharmaceutical (002262) Fundamentals 2026 — P/E 20.4x, Revenue Analysis | SniperIQ
Jiangsu Nhwa Pharmaceutical (002262) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥22.0B, trading at ¥21.68 on the SHZ. This SniperIQ fundamentals page covers Jiangsu Nhwa Pharmaceutical's valuation (P/E 20.4x, P/B 2.6x), profitability (net margin 17.9%), revenue (¥5.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Nhwa Pharmaceutical's market cap?
Jiangsu Nhwa Pharmaceutical (002262) has a market capitalization of approximately ¥22.0B, trading at ¥21.68 on the SHZ. Market cap moves with the live share price.
What is Jiangsu Nhwa Pharmaceutical's P/E ratio?
Jiangsu Nhwa Pharmaceutical's trailing twelve-month P/E ratio is 20.4x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Nhwa Pharmaceutical?
Jiangsu Nhwa Pharmaceutical runs a net profit margin of 17.9%, a gross margin of 70.3%, and an operating margin of 18.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Nhwa Pharmaceutical generate?
Jiangsu Nhwa Pharmaceutical reported revenue of ¥5.8B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 1.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Nhwa Pharmaceutical pay a dividend?
Jiangsu Nhwa Pharmaceutical offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jiangsu Nhwa Pharmaceutical financially healthy?
Jiangsu Nhwa Pharmaceutical carries a debt-to-equity ratio of 0.05x and a current ratio of 5.69x, with a market beta of -0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Nhwa Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Nhwa Pharmaceutical (002262) the key facts are: market cap ¥22.0B, P/E 20.4x, revenue ¥5.8B, 52-week range 17.96-29.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Nhwa Pharmaceutical's full fundamentals live
Get Jiangsu Nhwa Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.